What Ambros Therapeutics does

Ambros Therapeutics is a clinical-stage biotechnology company headquartered in Irvine, California, focused on developing neridronate for the treatment of Complex Regional Pain Syndrome Type 1 (CRPS-1), a rare and debilitating condition with approximately 50,000-70,000 new U.S. cases annually and no FDA-approved pharmacological therapies. The company was launched in December 2025 with an oversubscribed $125 million Series A co-led by RA Capital Management and Enavate Sciences (Patient Square Capital), and in-licensed exclusive North American rights to neridronate from Italian originator Abiogen Pharma, which has already commercialized the drug in Italy where it has been used in over 600,000 patients.

Neridronate is a differentiated third-generation bisphosphonate administered intravenously as a single cycle of four infusions over ten consecutive days. Ambros is advancing a precision-medicine patient-selection protocol — combining a positive triple-phase bone scan with attributes of the warm CRPS-1 subtype — to enrich for likely responders. The pivotal CRPS-RISE Phase 3 trial is a multicenter, randomized, triple-blind study enrolling approximately 270 participants in the United States, with the first patient dosed in June 2026. Neridronate holds FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations, and Ambros has received a USPTO Notice of Allowance on a method-of-use patent providing potential exclusivity through 2045.

Ambros is pre-revenue and currently makes money only in the sense of capital deployment against clinical milestones, not commercial sales. Its revenue model upon FDA approval will be specialty pharmaceutical sales of an IV-administered therapy distributed through specialty pharmacies and physician offices to CRPS-1 patients across the United States. The company is led by President and CEO Jay Hagan (ex-Regulus Therapeutics), with a management team drawn substantially from Regulus and other late-stage biotechs, and governance including co-founder Vivek Ramaswamy as a board member alongside representatives from RA Capital, Patient Square Capital, and Abiogen Pharma.

Name

Ambros Therapeutics

Legal name

Ambros Therapeutics, Inc.

Website

https://ambrostherapeutics.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Ambros Therapeutics is a clinical-stage biotechnology company developing neridronate, a third-generation bisphosphonate, as the first FDA-approved therapy for Complex Regional Pain Syndrome Type 1 (CRPS-1), serving an estimated 50,000-70,000 U.S. patients annually who currently have no approved pharmacological options.

Ownership category

akta.pro rank

Product category

Rare Disease Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Bisphosphonate therapy
• Rare disease treatment
• CRPS-1 therapeutics
• Clinical-stage biotechnology
• Pharmaceutical drug development

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Drug Sales: Pre-revenue clinical-stage biotech company. Plans to generate revenue through commercialization of neridronate for CRPS-1 upon FDA approval. The company licensed exclusive rights to neridronate in North America from Abiogen Pharma with an option for broader market expansion.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Ambros Therapeutics is a clinical-stage biotechnology company developing neridronate, a differentiated third-generation bisphosphonate drug candidate, for the treatment of Complex Regional Pain Syndrome Type 1 (CRPS-1). The company is advancing neridronate through the pivotal CRPS-RISE Phase 3 clinical trial in the United States under an exclusive North American license from Italian pharmaceutical company Abiogen Pharma.

Product overview

Ambros Therapeutics is a clinical-stage biotechnology company with a single focused pipeline targeting Complex Regional Pain Syndrome Type 1 (CRPS-1). The company's core product is neridronate, a differentiated bisphosphonate drug candidate, which is being advanced through the pivotal CRPS-RISE Phase 3 clinical trial. Neridronate represents a potential first-in-class treatment approach for a disease with no FDA-approved pharmacological therapies. The company was launched in December 2025 with $125 million Series A financing and licensed neridronate rights from Italian pharmaceutical company Abiogen Pharma S.p.A. for North American markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Neridronate Neridronate is a differentiated, third-generation bisphosphonate drug candidate targeting Complex Regional Pain Syndrome Type 1 (CRPS-1). Administered intravenously in a single cycle of 4 infusions over 10 days, it aims to safely reduce pain and improve quality of life for CRPS-1 patients. The drug has received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations and is already approved in Italy for CRPS and other bone diseases.

Quantifiable outcome

• First patient dosed in CRPS-RISE Phase 3 trial in June 2026
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Abiogen Pharma S.p.A.coreOEM/ Whitelabel/ Licensing Partner · 16 December 2025Abiogen Pharma granted Ambros Therapeutics exclusive licensing rights to neridronate in North America, with an option for broader market expansion. Neridronate was discovered, developed, and commercialized by Abiogen Pharma for the Italian market. Abiogen Pharma is a recognized leader in bisphosphonate innovation headquartered in Pisa, Italy.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Abiogen Pharma S.p.A. Italian pharmaceutical company that discovered, developed, and commercialized neridronate. Holds the exclusive North American license to Ambros and is both an investor and board member. Most direct comparable as the originator of Ambros's sole asset and operator of the established ex-US franchise.
• Trevena Inc. Clinical-stage biopharmaceutical company developing pain therapeutics, with a focus on novel mechanisms for acute and chronic pain. Comparable clinical-stage profile developing differentiated pain drugs through FDA approval pathways.
• Collegium Pharmaceutical: Specialty pharmaceutical company focused on responsible pain management, including abuse-deterrent formulations and treatments for chronic pain. Comparable go-to-market model targeting pain specialists with differentiated therapeutics.
• Grünenthal GmbH: Pain-specialty pharmaceutical company with active interest in CRPS-1 and other difficult-to-treat pain indications. Comparable business model of developing innovative therapies for underserved pain populations and is a direct competitor in the CRPS-1 development landscape.

Others

• Amneal Pharmaceuticals: Generic and specialty pharmaceutical company with a significant bisphosphonate portfolio used off-label for CRPS-1. Relevant as a potential off-label competitive threat that could constrain neridronate pricing and adoption if it gains FDA approval.

Broad incumbents

• Vertex Pharmaceuticals: Established biopharmaceutical company with a strong rare disease franchise (CF) and growing presence in pain (sickle cell, acute pain). Comparable business model of targeting rare/specialty indications with premium-priced therapies through specialty distribution.
• BioMarin Pharmaceutical: Established rare disease biopharmaceutical company with multiple orphan drug products and a focus on diseases with high unmet need. Comparable orphan-drug commercialization model and clinical-stage development approach for rare indications.
• Ultragenyx Pharmaceutical: Late-stage rare disease biopharmaceutical company commercializing multiple orphan therapies globally. Comparable go-to-market model targeting rare disease specialists with novel therapies.

Emerging players

• Harmony Biosciences: Specialty pharmaceutical company focused on rare neurological diseases, including narcolepsy and other CNS disorders with limited treatment options. Comparable orphan neurology commercial model targeting specialty physicians.
• Crinetics Pharmaceuticals: Late-stage clinical rare disease biopharmaceutical company developing novel therapies for endocrine conditions. Comparable clinical-stage rare disease development profile, specialty salesforce build-out, and orphan regulatory strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ambros-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ambros Therapeutics